Ciappenelli Robert D. 4
4 · Dicerna Pharmaceuticals Inc · Filed Jun 15, 2021
Insider Transaction Report
Form 4
Ciappenelli Robert D.
Chief Commercial Officer
Transactions
- Exercise/Conversion
Common Stock
2021-06-11$15.61/sh+10,000$156,100→ 13,773 total - Sale
Common Stock
2021-06-11$35.00/sh−10,000$350,000→ 3,773 total - Exercise/Conversion
Common Stock
2021-06-14$15.61/sh+20,000$312,200→ 23,773 total - Sale
Common Stock
2021-06-14$38.00/sh−20,000$760,000→ 3,773 total - Exercise/Conversion
Employee Stock Option (Right to Buy)
2021-06-11−10,000→ 290,000 totalExercise: $15.61Exp: 2029-06-30→ Common Stock (10,000 underlying) - Exercise/Conversion
Employee Stock Option (Right to Buy)
2021-06-14−20,000→ 270,000 totalExercise: $15.61Exp: 2029-06-30→ Common Stock (20,000 underlying)
Footnotes (4)
- [F1]The Reporting Person sold an aggregate of 10,000 shares of Common Stock on June 11, 2021 (the "Shares Sold No. 1") as reported in this Form 4. The Shares Sold No. 1 represent 2.08% of 481,298 shares of Common Stock, which is the number of shares of Common Stock owned by the Reporting Person prior to the Shares Sold No. 1 transaction reported in this Form 4, as well as shares issuable upon exercise or settlement of vested and unvested options and restricted stock units held by the Reporting Person as of the date of this report.
- [F2]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 10, 2020.
- [F3]The Reporting Person sold an aggregate of 20,000 shares of Common Stock on June 14, 2021 (the "Shares Sold No. 2") as reported in this Form 4. The Shares Sold No. 2 represent 4.24% of 471,298 shares of Common Stock, which is the number of shares of Common Stock owned by the Reporting Person prior to the Shares Sold No. 2 transaction reported in this Form 4, as well as shares issuable upon exercise or settlement of vested and unvested options and restricted stock units held by the Reporting Person as of the date of this report.
- [F4]The option vests 25% on the first year anniversary of the vesting start date of June 3, 2019 and the remaining 75% vests in 36 substantially equal monthly installments thereafter, subject in each case to the Reporting Person's continued employment or service with the Issuer through the applicable vesting date.